CytoDyn Names Richard Pestell, M.D., Ph.D. as Lead Oncology Consultant
CytoDyn, a biotechnology company known for developing leronlimab, a promising CCR5 antagonist drug for various therapeutic uses, recently appointed Dr. Richard Pestell, M.D., Ph.D., as Lead Consultant for Preclinical and Clinical Oncology. Dr. Pestell brings with him over thirty years of research experience in the field and a strong track record of investigating new drug products and therapies.
Currently serving as the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute, Dr. Pestell has had a significant impact on cancer research. His work has been widely recognized and published in over 600 publications, accumulating an impressive 95,000 citations along the way.
In his new role at CytoDyn, Dr. Pestell will be instrumental in guiding the company’s research and development strategy in oncology. With his expertise and expansive network, CytoDyn aims to further explore the potential of leronlimab in cancer treatment. The company has already made strides in this area, including obtaining Fast Track Designation from the FDA for the use of leronlimab in combination with carboplatin for metastatic triple-negative breast cancer patients.
Dr. Jacob Lalezari, CEO of CytoDyn, expressed his excitement at Dr. Pestell joining the team, noting that his insights and expertise will be invaluable in advancing their clinical development pipeline in oncology. Dr. Pestell himself is enthusiastic about the potential of leronlimab to improve patient care and expand treatment options in oncology, aiming to leverage the drug’s capabilities to enhance outcomes for cancer patients.
With a medical degree from the University of Western Australia, a Ph.D. from the University of Melbourne, and extensive postdoctoral research experience, Dr. Pestell is well-equipped to lead CytoDyn’s efforts in oncology. His numerous awards and accolades reflect his contributions to the field of cancer research, and his recent appointment as Lead Consultant in Oncology further solidifies his position as a key player in the fight against cancer.
CytoDyn’s focus on developing leronlimab, an investigational antibody that targets CCR5, is part of its commitment to studying cancer and inflammation, among other potential indications. The company is dedicated to advancing the field of oncology and improving patient outcomes through innovative research and development efforts.
